Michael Krainer Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center Medical University of Vienna Biography Publications Institution JoVE Articles Michael Krainer has not added a biography. If you are Michael Krainer and would like to personalize this page please email our Author Liaison for assistance. Publications Loss of HCRP1 Leads to Upregulation of PD-L1 Via STAT3 Activation and is of Prognostic Significance in EGFR-dependent Cancer Translational Research : the Journal of Laboratory and Clinical Medicine. Apr, 2021 | Pubmed ID: 33197651 Impact of Frailty on the Management of Patients with Gynecological Cancer Aged 80 years and Older Archives of Gynecology and Obstetrics. 02, 2021 | Pubmed ID: 33009994 Thirteen-year Analyses of Medical Oncology Outpatient Day Clinic Data: a Changing Field ESMO Open. 10, 2020 | Pubmed ID: 33051192 Erratum to 'Clinical Progression is Associated with Poor Prognosis Whatever the Treatment Line in Metastatic Castration-resistant Prostate Cancer: The CATS International Database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163] European Journal of Cancer (Oxford, England : 1990). Sep, 2020 | Pubmed ID: 32723589 Corrigendum to "Clinical Progression is Associated with Poor Prognosis Whatever the Treatment Line in Metastatic Castration Resistant Prostate Cancer: The CATS International Database" [Eur J Canc 125, (January 2020) 153-163] European Journal of Cancer (Oxford, England : 1990). Sep, 2020 | Pubmed ID: 32605716 Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer Cancers. Feb, 2020 | Pubmed ID: 32120793 Clinical Progression is Associated with Poor Prognosis Whatever the Treatment Line in Metastatic Castration Resistant Prostate Cancer: The CATS International Database European Journal of Cancer (Oxford, England : 1990). 01, 2020 | Pubmed ID: 31787484 Assessment of Body Composition in the Advanced Stage of Castration-resistant Prostate Cancer: Special Focus on Sarcopenia Prostate Cancer and Prostatic Diseases. 06, 2020 | Pubmed ID: 31745255 Synthetic Lethality Guiding Selection of Drug Combinations in Ovarian Cancer PloS One. 2019 | Pubmed ID: 30682083 Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database European Urology Oncology. 12, 2018 | Pubmed ID: 31158090 Synthetic Lethal Combinations of Low-toxicity Drugs for Breast Cancer Identified by Genetic Screens in Yeast Oncotarget. Nov, 2018 | Pubmed ID: 30555636 LUBAC and ABIN-1 Modulate TRAIL-Based NF-κB Induction in Human Embryonic Kidney 293 Cells BioResearch Open Access. 2018 | Pubmed ID: 29862142 Analysis of Hematological Parameters As Prognostic Markers for Toxicity and Survival of Radium Treatment Oncotarget. Mar, 2018 | Pubmed ID: 29662636 Efficacy of Cabazitaxel Rechallenge in Heavily Treated Patients with Metastatic Castration-resistant Prostate Cancer European Journal of Cancer (Oxford, England : 1990). 07, 2018 | Pubmed ID: 29636272 Efficient Leukocyte Depletion by a Novel Microfluidic Platform Enables the Molecular Detection and Characterization of Circulating Tumor Cells Oncotarget. Jan, 2018 | Pubmed ID: 29416657 The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' Field-tested in Infrequent Tumour Entities: an Extended Analysis of Its Feasibility at the Medical University of Vienna ESMO Open. 2017 | Pubmed ID: 28761758 Increased Genitourinary Fistula Rate After Bevacizumab in Recurrent Cervical Cancer Patients Initially Treated with Definitive Radiochemotherapy and Image-guided Adaptive Brachytherapy Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al]. Dec, 2017 | Pubmed ID: 28721510 The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in Daily Practice: a Single Institution, Real-life Experience at the Medical University of Vienna ESMO Open. 2016 | Pubmed ID: 27843624 Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 09, 2016 | Pubmed ID: 27400947 The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma PloS One. 2015 | Pubmed ID: 26248232 Tumor Suppressor Candidate 3 (TUSC3) Prevents the Epithelial-to-mesenchymal Transition and Inhibits Tumor Growth by Modulating the Endoplasmic Reticulum Stress Response in Ovarian Cancer Cells International Journal of Cancer. Sep, 2015 | Pubmed ID: 25735931 HIF1α Regulates MTOR Signaling and Viability of Prostate Cancer Stem Cells Molecular Cancer Research : MCR. Mar, 2015 | Pubmed ID: 25349289 The Potential Evasion of Immune Surveillance in Mucosa Associated Lymphoid Tissue Lymphoma by DcR2-mediated Up-regulation of Nuclear Factor-κB Leukemia & Lymphoma. May, 2015 | Pubmed ID: 25248880 Distinctive Outcome in Patients with Non-uterine and Uterine Leiomyosarcoma BMC Cancer. Dec, 2014 | Pubmed ID: 25523155 Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: a Randomized, Controlled, Biomarker Study PloS One. 2014 | Pubmed ID: 24755958 TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in Vivo Scientific Reports. Jan, 2014 | Pubmed ID: 24435307 HVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2011 | Pubmed ID: 22016507 Recurrence-free Survival in Prostate Cancer is Related to Increased Stromal TRAIL Expression Cancer. Mar, 2011 | Pubmed ID: 21381010 Assessment of a Six Gene Panel for the Molecular Detection of Circulating Tumor Cells in the Blood of Female Cancer Patients BMC Cancer. Dec, 2010 | Pubmed ID: 21129172 Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer Molecular Cancer Therapeutics. Apr, 2010 | Pubmed ID: 20371719 The Role of C-FLIP(L) in Ovarian Cancer: Chaperoning Tumor Cells from Immunosurveillance and Increasing Their Invasive Potential Gynecologic Oncology. Jun, 2010 | Pubmed ID: 20227749 BAMBI is Overexpressed in Ovarian Cancer and Co-translocates with Smads into the Nucleus Upon TGF-beta Treatment Gynecologic Oncology. May, 2010 | Pubmed ID: 20189233 Linking the Ovarian Cancer Transcriptome and Immunome BMC Systems Biology. Jan, 2008 | Pubmed ID: 18173842 A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine As First Line Chemotherapy in Patients with Androgen Independent Prostate Cancer The Journal of Urology. Jun, 2007 | Pubmed ID: 17509302 Promoter Hypermethylation of GSTP1, AR, and 14-3-3sigma in Serum of Prostate Cancer Patients and Its Clinical Relevance The Prostate. Mar, 2007 | Pubmed ID: 17192910 Five Genes from Chromosomal Band 8p22 Are Significantly Down-regulated in Ovarian Carcinoma: N33 and EFA6R Have a Potential Impact on Overall Survival Cancer. Dec, 2005 | Pubmed ID: 16270321 A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions Maximilian Marhold1, Andreas Heinzel2, Almas Merchant1, Paul Perco3, Michael Krainer1 1Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, 2Department of Nephrology, Medical University of Vienna, 3Department of Internal Medicine IV, Medical University Innsbruck JoVE 60328 Cancer Research
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions Maximilian Marhold1, Andreas Heinzel2, Almas Merchant1, Paul Perco3, Michael Krainer1 1Department of Internal Medicine I - Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, 2Department of Nephrology, Medical University of Vienna, 3Department of Internal Medicine IV, Medical University Innsbruck JoVE 60328 Cancer Research
